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Metabolic consequences of high mass-transfer hemodialysis. The
metabolic fate of acetate (Ac) infused during hemodialysis and the
acid-base changes attendant to its conversion to bicarbonate were
studied in 20 patients. Twenty-eight studies were performed under
three conditions: group 1, 40 mmoles/liter of Ac dialysate; group
2, 30 mmoles/liter of Ac dialysate; and group 3, bicarbonate-
buffered dialysate. Fasting patients were dialyzed using 2.5 m2
hollow fiber dialyLers. Patients remained fasting for 4 hr after
dialysis and were observed for 48 hr. Total acetate infused was
highest for group I patients. The maximum acetate utilization rate
was 48 ,2moles/min/kg of body wt. Peak plasma acetate values
were 5.1 mmoles/liter when the rate of acetate infusion approxi-
mated maximum utilization, and were 10.2 mmoles/liter when the
maximum utilization rate was exceeded. Significant bicarbonate
removal occurred during hemodialysis (group 1, 848 mmoles;
group 2, 676 mmoles). In group I and 2 patients, the intradialytic
bicarbonate removal rate exceeded the bicarbonate generation
rate, causing serum bicarbonate concentrations to decrease, and
peak postdialysis bicarbonate concentrations did not occur until
four hours. The carbon dioxide pressures of groups I and 2
dropped significantly early in dialysis and accounted for any pH
rise occurring during dialysis. The proportion of estimated acetate
metabolized to bicarbonate was 93.5% in group I and 91.1% in
group 2. Acute changes in plasma lipid patterns were the same in
all groups. These results indicate that high mass-transfer hemo-
dialysis can result in excessive acetate infusion, marked bicarbo-
nate removal, and carbon dioxide dialysance, which have signifi-
cant impact on the patient's acid-base status, and that immediate
equimolar conversion of acetate to bicarbonate does not occur
during dialysis.
Consequences métaboliques de l'hémodialyse a haut rendement de
transfert de solutés. Le devenir mtabolique de l'acétate (Ac) ad-
ministré au cours de l'hémodialyse et les modifications acido-
basiques consécutives a sa conversion en bicarbonate ont été étu-
dies chez 20 malades. Vinghuit etudes ont été réalisées dans 3
conditions: groupe 1, dialysat 40 m en Ac; groupe 2, dialysat 30
m en AC; et groupe 3: dialysat tamponné avec bicarbonate.
Les malades 4 jeun ont été dialyses au moyen de fibres creuses de
2,5 m2. Les malades sont restés àjeun pendant 4 hr après Ia dialyse
et ont été suivis pendant 48 hr. La quantité totale d'Ac transférée a
été Ia plus élevée chez les malades du groupe 1. Le debit maximum
d'utilisation de I'acétate a Cté de 48 imoIes/min/kg. La valeur Ia
plus Clevée de l'acétate plasmatique a été de 5,1 mmoles/liter
quand le debit de transfert était voisin de l'utilisation maximale et
de 10,2 mmoles/liter quand l'utilisation maximale a Cté depassée.
Une soustraction significative de bicarbonate a etC observée au
cours de l'hémodialysc (groupe 1, 848 mmoles; groupe 2, 676
mmoles). Dans les groupes I et 2 Ia soustraction de bicarbonate
intradialytique a été supérieure a Ia génération de bicarbonate ce
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qui a déterminé une baisse de bicarbonate pendant dialyses. La
valeur maximale de bicarbonate post-dialytique n'a pas été obtenue
avant Ia 4e heure. Les P0 des groupes I et 2 ont baissé signifi-
cativement au debut de Ia dialyse et les valeurs expliquaien l'aug-
mentation du pH observée pendant Ia dialyse. La proportion
d'acétate mCtabolisée en bicarbonate a été de 93.5% dans le groupe
I et de 9 1,1% dans le groupe 2. Les modifications aiguës des lipides
du plasma ont été semblables dans les différents groupes. Ces
résultats indiquent que l'hemodialyse 4 haut rendement de trans-
fert peut avoir pour consequence one administration excessive
dacCtate, une soustraction de bicarbonate importante et one
dialysance du gaz carbonique qui ont des consequences impor-
tantes sur l'état acido-basique du malade. Ils indiquent aussi que
a conversion Cquimolaire de I'acétate en bicarbonate ne se pro-
duit pas immédiatement au cours de Ia dialyse.
The correction of the metabolic acidosis of uremia
is a fundamental function of hemodialysis. The alka-
linizing salt in almost universal use in dialysate is
sodium acetate. Its choice to replace sodium bicarbo-
nate presumes a rapid peripheral utilization and
equimolar oxidative generation to sodium bicarbo-
nate via the tricarboxylic acid pathway [1]. It has
been estimated that man can metabolize up to 300
mmoles/hr of acetate [2], but recent evidence sug-
gests that the maximum rate of utilization in dialysis
patients is somewhat slower [3]. Kveim estimated the
maximum utilization rate to be 3.5 mmoles/hr/kg of
body wt [3].
In recent years, the use of large surface area dialy-
zers, higher blood flows, and high dialysate acetate
concentrations (35 to 40 mmoles/liter) has resulted in
the administration of a considerable acetate load to
hemodialysis patients. Some authors [4, 5] have im-
plied that contemporary hemodialysis methods may
cause acetate infusion at a rate above the maximum
at which it can be metabolized via the tricarboxylic
acid cycle. A possible consequence of a massive ace-
tate load is diversion of the acetate into alternate
metabolic pathways. Acetate occupies a central role
in carbohydrate and lipid metabolism. After cellular
conversion of acetylcoenzyme A, it can be metabo-
lized to carbon dioxide and water; it can undergo
condensation to malonylcoenzyme A and enter fatty
acid synthesis, or it can be converted to hydroxy-
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methyiglutarylcoenzyme A and enter metabolic path-
ways forming ketone bodies, terpenes, and choles-
terol [6, 7].
We have investigated hemodialysis patients to de-
termine: 1) the acetate metabolic rate under circum-
stances of hemodialysis; 2) the effects of rapid admin-
istration of large amounts of sodium acetate on acute
alterations of acid-base status; 3) the proportion of
acetate entering the tricarboxylic cycle and that
which may be available for entry into alternate meta-
bolic pathways; and 4) the presence of possible acute
alterations of plasma lipid patterns which could be
attributable to the integral role of acetylcoenzyme A
in lipid metabolism.
Methods
Patients. Outpatients with a mean age of 47.1 9.7
(± ISD) yr, who had chronic renal failure with an
endogenous creatinine clearance of less than 3
ml/min and a residual urine volume of 200 to 800
mi/day, were chosen for study. All patients were
receiving 6-hr hemodialyses three times a week, using
either 1.0 m2 coil or 1.3 m2 hollow fiber dialyzers.
Patients receiving this treatment for at least three
consecutive months were considered to be "estab-
lished" on the therapy. "New" patients had received
treatment for less than one month. Individuals with
diabetes mellitus, hepatic insufficiency, pericarditis,
congestive heart failure, or a hematocrit less than
20% were excluded. One patient had an abnormal
hemoglobin (30% Hgb S).
Each patient was on a diet consisting of at least
0.75 g of protein/kg of body wt per day with car-
bohydrate and polyunsaturated fat individually pre-
scribed to maintain an ideal body weight. Drug ther-
apy included multivitamins, folate, aluminum
hydroxide, and ferrous fumarate. In addition, some
patients received antihypertensives (6 of 20 patients)
or adrogenic steroids (2 of 20 patients) at the time of
study.
Twenty-eight studies were performed on 20
patients under conditions of a) high dialysate acetate
concentration (group I), b) moderate dialysate ace-
tate concentration (group 2), and c) buffered bicarbo-
nate dialysate with no acetate (group 3) (Table 2). Six
patients were studied twice, one person was studied
three times.
Hemodialysis procedure and performance. Glucose-
free dialysate was used exclusively in this study. The
dialysate of patients in group I was continuously
prepared from a commercial concentrate (Hemo-
trate, McGaw, Glendale, CA) and delivered by a
single pass proportioning unit (Milton Roy, Park
Ridge, IL) at a rate (QD) of 500 mI/mm (volumetric
calibration), yielding a mean acetate concentration of
40 mmoles/liter at the dialyzer inlet (Table I). The
dialysate of patients in group 2 was batch-prepared
from concentrate (Hemotrate®) in 200-liter volumes
in a recirculating single pass system (Travenol, Mor-
ton Grove, IL) and delivered to the recirculating
chamber at a QD of 500 mI/mm. A negative pressure
converter (Cordis Dow, Miami, FL) delivered dialy-
sate with a mean dialyzer inlet acetate concentration
of 30 mmoles/liter.
The dialysate of patients in group 3 was batch-
prepared by adding the following salts to each 200-
liter bath: sodium chloride, 1150 g; sodium bicarbo-
nate, 604 g; potassium chloride, 30 g; magnesium
chloride, 30 g; and calcium chloride, 32 g. Initially,
the pH was adjusted to 7.4 with 6 N hydrochloric acid
and maintained by bubbling 10% carbon dioxide and
balanced air mixture through the reservoir and re-
circulating chambers at 5 to 7 liters/mm. The group 3
delivery system was the same as in group 2 studies.
Electrolyte and acetate dialysate concentrations were
sampled from the dialyzer inlet. All patients were
dialyzed with 2.5 m2 hollow fiber artificial kidneys
(Cordis Dow, Miami, FL).
Vascular access was provided by external shunts (5
patients), a bovine heterograft (1 patient), and arte-
riovenous fistulae (14 patients). In the fistula group, a
separate true arterial line was established at a distant
site. A double roller blood pump (Travenol, Morton
Grove, IL) was used; blood flow rates (QB) were
calibrated volumetrically in vitro and verified during
dialysis with a 50-cm race track and blood flow mon-
itor (Renal Systems, Minneapolis, MN). Alterations
in body weight were minimized by keeping blood
flow rates and dialysate negative pressure (50 mm
Hg) constant throughout dialysis. Ultrafiltration rate
(QF) in group I patients was estimated from careful
measurements of fluid balance and weights; for
groups 2 and 3, QF was determined from the differ-
ence of recirculating chamber inlet and outlet dialy-
sate volumes collected over 5-mm periods. Ultrafil-
trate and blood loss from samples were replaced with
normal saline. Anticoagulation was achieved with
bolus doses of heparin given as 60 U/kg of body wt
initially, 15 U/kg at hours one and two, and 7.5 U/kg
at hour three.
Fasting (12 hr) patients received a 4-hr hemo-
dialysis and remained fasting after dialysis for 4 hr.
Weight was taken before and after dialysis. For those
individuals with significant urine production, the
bladder was emptied prior to dialysis, and urine was
collected for renal acetate clearance and bicarbonate
excretion. Follow-up specimens were drawn from
fasting patients (12 hr) at 24 and 48 hr after initiation
of hemodialysis.
Blood and dialysate samples for electrolytes, urea,
368 To/chin et a!
Table I. Measured dialysate solute characteristics
Solute
Group I
mEq/Iitera
Group 2
mEq/liter°
Group 3
rnEq/1i1era
Sodium
Acetate
Bicarbonate
Chloride
Potassium
Calcium
Magnesium
139.0 + 1.0
40.0 + 1.8
0.0
108.0 3.0
2.0 0.1
3.3 + 0.5
1.6 + 0.2
136.0 + 3.5
30.0 2.7
4.2 1.3
104.0 2.3
2.1 0.2
3.2 0.4
1.4 + 0.3
132.0 4.0
0.0
30.2 2.8
103.0 + 4.0
2.0 + 0.2
3.1 0.4
1.6 0.3
a + iso.
creatinirie, uric acid, and glucose were drawn hourly
with the exception of glucose and uric acid (2nd and
4th hr only) and were measured by standard tech-
niques (Technicon). The clearance (Table 3) and
dialysance for urea, creatinine, bicarbonate, uric
acid, and glucose for each of the study groups was
determined from plasma samples drawn simultane-
ously across the dialyzer; no attempt was made to
correct for solute disequilibrium which might exist
between plasma and red blood cells. Calculations for
clearance and dialysance were based on a modifica-
tion of Wolf's formulae [8] (Appendix, equations la
and b).
Blood samples for blood gas analysis (Table 4),
electrolytes, lactate, and pyruvate (Table 6) were
drawn before, during, and after dialysis. Samples for
acetate determinations were drawn hourly during
dialysis (Fig. I), serially immediately after dialysis
(Fig. 2), and monitored subsequently at 8, 24, and 48
hr after initiation of the study. Specimens for total
cholesterol, fatty acids, triglycerides, lipoprotein elec-
trophoresis, acetoacetate, acetone, ethanol, and acet-
aldehyde were collected sequentially throughout the
study (Figs. 3 and 4). True arterial samples for ace-
tate and gas analysis were obtained in fistula patients,
along with the simultaneous arterial dialyzer line
specimens.
Acid-base metabolism. Blood samples for pH, car-
bon dioxide pressure (pCO2), and oxygen pressure
(p02) were drawn anaerobically in heparinized sy-
ringes, iced, and analyzed immediately with gas ana-
Table 2. Patient groups
Group I Group 2 Group 3
40mmoles 30mmoles Bicarbonate
Variablra acetate acetate bath
N(studies) 8 10 10
Age,years so 46.5 9.0 43.1 + 15.0 49.0 + 11.0
Established patients, % 50% 60% 60%
Male patients, % 63% 40% 60%
Prior interdialytic
interval.hr so 50.0 12.0 48.5 + 20.0 44.0 + 14.0
Predialysis serum
creatinifle
,ng/cII/kg + so 0.14 + 0.04 0.15 0.03 0.14 0.03
a No statistical difference among groups for each variable.
Table 3. In vivo performance characteristics of the 2.5 m2 hollow
fiber artificial kidney
Clearance
mi/mm + SCM
Group I Group 2 Group 3
Solute (N 8) (N = 10) (N 10)
Creatinine 169.0 + 6.3 135.4 6.6 138.3 + 575
Urea 220.0 6.0 122.7 2.2c 124.7 435
Bicarbonate 208.0 + 9.2 130.2 7.IC
Uric acid 147.0 + 5.2 — 107.4 + 47b
Glucose 175.8 10.9 — 124.2 3.2"Q' 280.0 + 10.0 270.2 10.0 291.0 4.2
No statistical significance between groups for blood flow (QH).
Significance group I vs. 3 (P < 0.001).
Significance group I vs. 2 (P < 0.001).
lyzers (Radiometer, Copenhagen, Denmark; Instru-
mentation Laboratory, Lexington MA). These
instruments were calibrated prior to each use, and
accuracy was verified using standards (Blood Gas
Analyzer Systems Control®, General Diagnostics,
Morris Plains, NJ) over a pH range of 7.03 to 7.63;
the pH determinations varied + 0.02 pH units. The
variance of the pCO2 (+ 1.3 mm Hg) and the P°2 (±
9.1 mm Hg) was determined under the same pH
conditions. Dialysate samples were processed sim-
ilarly. Minute ventilation volume (MVV) was mea-
sured with a respirometer (Wright).
Actual bicarbonate was calculated by the methods
of Sigaard-Anderson [9] and Thomas [10]. The
anion gap was determined as follows: (sodium +
potassium) — (chloride + bicarbonate). Lactate was
measured using the Dupont ACA enzymatic (NAD-
LDH) system. Pyruvate was determined by pre-
viously reported techniques [11].
Acetate metabolism. For group I and 2 patients,
plasma acetate concentrations were determined for
calculation of acetate kinetics. Because of disequilib-
rium between red blood cell (RBC) and plasma ace-
tate concentrations, separate studies were undertaken
to determine arterial and venous dialyzer RBC and
plasma acetate concentrations under the same condi-
tions as those of the study groups. Twenty studies
were performed in four patients at regular intervals
during a four-hour dialysis period. Heparinized
blood was iced immediately, and duplicate samples
were 1) sonicated and frozen immediately for sub-
sequent whole blood acetate determination, or 2) cen-
trifuged, the plasma removed, RBCs sonicated, and
the separate plasma and RBC aliquots frozen imme-
diately for subsequent plasma and RBC acetate de-
terminations. The hematocrit and volume of RBC
ghosts of sonicated whole blood were determined for
each sample. Red blood cell ghosts accounted for less
than 1% of whole blood volume.
Total blood acetate concentration measured from
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Tabte 4. Respiratory and metabolic changes during and after hemodialysis
Fir pH, + SD P00,,mm Hg HCO3, mmoles//iter
Group I Group 2 Group 3 Group I Group 2 Group 3 Group I Group 2 Group 3
0 7.38 0.04 7.41 + 0.02a 7.38 0.04 35.4 + 4.1 35.5 + 2.6 35.6 + 4.2 20.5 3.9 21.7 2.4 19.7 1.9
I 7.38 0.06 7.42 0.04 7.40 0.03 28.8 + 4.2 29.3 + 4,3a 349 43b 16.2 2.1K 18.3 Isa 20.9 + 2.2d
2 7.42 0.05 7.43 + 0.04 7.42 0.03 25.6 4.2 28.0 34 345 43d 15.4 2.1K 18.5 + 2.4 21.4 j7d
3 7.41 0.04 7.43 0.04 7.43 0.03 25.8 4.0 28.4 5.1° 347 4.0" 15.8 2.3 18.5 + 2.6' 22.3 2.2"
4 7.4! 0.04 7.45 + 0.04 7.45 0.02 25.2 + 4.2 27.9 4.3' 33.2 5.!" 15.6 + 2.I 19.2 3.1° 22.6 2.1°
8 7.48 0.05 7.47 + 0.05 7.44 + 0.03 33.7 4.5 32.0 + 3.! 32.9 2.5 23.8 + 2.4 22.7 + 3.0 21.6 1.4
24 7.42 0.04 7.4! 0.04 7.4! 0.03 34.7 2.9 34.9 2.0 35.0 3.! 22.3 2.2 21.9 + 2.8 20.5 .8
48 7.39 0.04 7.40 0.03 7.37 0.04 34.1 2.6 34.8 3.9 33.0 2.8 19.5 1.9 20.9 + 2.2a 18.5 1.7
Significance, group 2 vs. 3 (P < 0.05).
"Significance, group I vs. 3 (P < 0.05).
Significance, group I vs. 2 (P < 0.01).
Significance, group I vs. 3 (P < 0.001).
Significance, group 2 vs. 3 (P < 0.005).
Significance, group 2 vs. 3 (P < 0.0!).
Significance, group I vs. 2 (P < 0.05).
Significance, group I vs. 3 (P < 0.0!).
sonicated whole blood and total blood acetate calcu-
lated from the plasma and RBC acetate concentra-
tions were within + 1%. There were no significant
differences in the arterial RBC to plasma acetate
ratios at one, two, and four hours of dialysis (P >
0.1). This was also true for the venous dialyzer outlet
values. Arterial RBC acetate was 0.59 + 0.09 (+ 1
SD) that of arterial plasma acetate concentration, and
venous dialyzer line RBC acetate was 0.49 0.08
that of the venous line plasma acetate (Appendix,
equation 2b and c).
Samples for group I and 2 studies were iced, sepa-
rated, and analyzed immediately, or frozen and
stored. There was no loss of acetate in frozen samples
stored for as long as three weeks.
12
11
10
0
0
For acetate analysis, samples (plasma, sonicated
RBCs or whole blood, and dialysate) were diluted
with distilled water, acidified with hydrochloric acid,
and analyzed in a gas chromatographic apparatus.
The analysis conditions were: Porapak Q column (91
>< 0.2 cm) in glass; temperature, 160°C; nitrogen flow
rate, 40 ml/min; and detection with a flame ioniza-
tion detector. Acetate concentration was calculated
by comparing the peak height of the patients' chro-
"K
0
0
0
12
10
• Group 1
£ Group 2
4
Time, hr
Fig. I. Plasma ace/ate concentralion.s during hem odialy.sis. + repre-
sents SEM.
0
30
Postdialysis time, rn/n
Fig. 2. Disappearance of p/anna acetate in the i,nmediaie post-
dial vs/s period. represents I SI).
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0
0
E0
a0
0
matogram to four simultaneously run acetic acid
standards ranging from 20 to 80 mg/dl (undiluted).
The standard solutions were calibrated prior to each
group of determinations. Peak chromatographic
height showed a linear relation to increasing concen-
trations of the standard solutions. The coefficient of
variance for this method is over a range of
plasma acetate concentrations of 0.1 mmoles/liter, to
240 mmoles/liter. Values less than 0.1 mmoles/liter
were reported as trace amounts. With this method, 20
normal fasted volunteers had no detectable circulat-
ing acetate. Trace amounts of circulating acetate were
detected in only 2 out of 84 measurements in fasting
dialysis patients.
Mass transfer of acetate (acetate infused) was cal-
culated (Appendix, equation 3) for each hour of
dialysis from the mass transfer rate for acetate (Ap-
pendix, equation 2a). The average rate of acetate
infusion during dialysis was calculated from the total
acetate infused (Appendix, equation 4). The max-
imum rate of utilization of exogenous acetate was
calculated from hourly true arterial levels when con-
secutive values remained constant or increased
slightly (<10%). Assuming this represented stabiliza-
tion of the total body acetate pool, the amount me-
tabolized in that hour was considered equivalent to
the amount infused (Appendix, equation 5) [3]. Ace-
tate disappearance rate was calculated from the post-
dialysis data (Appendix, equation 6).
Estimation of entry of sodium acetate into the tn-
carboxylic acid cycle. The determination of the propor-
tion of infused acetate metabolized in the tricarboxy-
lie acid cycle was carried out by estimation of changes
in the total body bicarbonate during and after acetate
infusion (Table 5).
The total amount of acetate infused during hemo-
dialysis was calculated using the Fick principle (Ap-
pendix, equations 3a and b). At the start of dialysis,
the total body bicarbonate was estimated from the
actual serum bicarbonate concentration (Appendix,
equation 7a). The bicarbonate space was taken to be
60% of the total body wt [12—14]. The rate and total
amount of bicarbonate removed during hemodialysis
were estimated (Appendix, equations 7b and c, 10).
Total bicarbonate generated was calculated for the
period during and after dialysis (Appendix, equations
7d, e, and f). The peak postdialysis serum bicarbo-
nate concentration was used to compute the post-
dialysis total body bicarbonate concentration and the
total bicarbonate generated (Appendix, equation 7e
Table 5. Estimated acetate and bicarbonate kinetics during hemodialysis0
Groups
Total bicarbonate
removed (1. HCO,)
mmoles + SD
Total bicarbonate
generated (T. HC030)
mmoles SD
Total infused
acetate (T. lnf. Ac)
mmoles + SI)
Acetate
converted (MA)
% + SEM
I 848.0 + 100.0" 980.6 214.0" 048.3 + 00.5" 93.5 4.8
(range) (701.0 to 103.0 mmoles) (632.0 to 1193.0 mmoles) (966.0 to 1190.0 mmoles) (66.0 to 106.0%)
2 676.0 + 154.0
(range) (400.0 to 883.8 mmoles)
° The method for calculating the kinetic data is outlined in the Appendix (equations 7a-f, 8).
"Significance I vs. 2, P < 0.01.
Triglycerides I—)
and cholesterol (———I
concentrations
0t1t
F
Non-esterif led free fatty acids
concentration
a
0-
Lu
F
6 8
Time, hr
Fig. 3. Plasma lipid changes during and after dialysis.
2 3 4 6 8
Time, hr
Fig. 4. Serum acetoacetale concentration during and after dialysis. I
represents I SD. Group I levels were significantly greater than
Group 2 or 3 levels by mid-dialysis (P K 0.005).
723.9 190.0
(467.0 to 960.0 mmoles)
780.4
(568.0 to 959.0
145.6
mmoles)
91.1 + 3.5
(77.0 to 106.0%)
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and f). The proportion of infused acetate entering the
tricarboxylic acid cycle was estimated from the ap-
parent bicarbonate generation (Appendix, equation
8). The calculation of the rate of bicarbonate gener-
ation during dialysis was based on changes in total
body bicarbonate estimates (Appendix, equations 9a,
b, and c).
Lipids and acetate metabolites. Total serum choles-
terol was measured by autoanalyzer using the Zak-
Slatkis color reaction after isopropanol extraction
(Technicon). Total triglycerides were also measured
by autoanalyzer using phospholipid extraction, sa-
ponification of the triglycerides, and release and mea-
surement of the freed glycerol [15]. Lipoprotein elec-
trophoresis was performed with agarose gel (Corning
AC!, Universal Electrophoresis System). Serum ace-
tone was measured by gas chromatography [16]. Aceto-
acetate was measured using serial sample dilutions
[17]; the trace amount of acetoacetate was the dilu-
tional endpoint of the assay. Comparison acetoacetate
standard solutions were used to determine the con-
centration in the patients' samples (Fig. 4). Increas-
ing concentrations of the standard solutions demon-
strated a linear relationship to the detectability of
acetoacetate in progressively more dilute samples.
Acetoacetate presence in an undiluted sample repre-
sented a concentration of 0.5 mmoles/liter, a positive
1: 2 dilution represented 1.0 mmoles/liter, a 1:4 dilu-
tion was equivalent to 1.7 mmoles/liter, and a 1:8
dilution equaled 3.0 mmoles/liter. The coefficient of
variance of this method was +8.0%; the recovery rate
of the method was 99.0%. Gas chromatography was
used to measure ethanol and acetaldehyde. Analysis
conditions were similar to those of acetate determina-
tions, except for lower column temperatures.
Plasma samples for total nonesterified fatty acids
were iced, immediately separated, and frozen at
—70°C. These were analyzed according to published
techniques [18,19]. Results were reported in mEq/liter
to avoid assumption of fatty acid chain length.
Statistical analysis. Group means were examined
for significant differences by Student's t test. Correla-
tion of two variables was done by linear regression
analysis [20].
Results
Patients. Patients in all study groups tolerated
hemodialysis without obvious clinical adverse effects.
No significant episodes of hypotension (systolic
blood pressure < 110 mm Hg) occurred during
dialysis. The body weight decrease in group 1 was 0.5
kg + 0.2 (± I SD), in group 2 it was 0.7 + 0.2 kg, and
in group 3, 0.6 + 0.1 kg; there were no significant
weight differences among groups or between pre- and
postdialysis weights (P > 0.1). The mean serum
creatinine values at 48 hr were not significantly differ-
ent (P > 0.1) from the predialysis values (Table 2).
Solute mass-transfer. The 2.5 m2 hollow fiber arti-
ficial kidney provided efficient solute transfer during
hemodialysis (Table 3). The clearance of small so-
lutes was significantly greater for group I studies than
group 2 and 3 studies. In group 2 and 3 patients,
however, mean dialysance values for the same solutes
were not significantly different from group 1 (group 1:
creatinine, 169.0 mI/mm 6.3 [± 1 SEM]; urea, 220.6
6.0 ml/min; group 2: creatinine, 171.9 + 4.0
mI/mm; urea, 210.1 + 8.4 mI/mm; group 3: creati-
nine, 173.0 + 5.3 ml/min; urea, 221.0 + 8.7 mI/mm)
(P > 0.1), verifying that dialyzer performance was
consistent throughout the investigation. Mean blood
flow values were similar in all groups. During hemo-
dialysis, glucose transfer resulted in the loss of 180.0
3.0 mmoles (± 1 SD) of glucose from each patient.
A small concentration of glucose (27.0 1.4 mg/dl)
accumulated in the recirculating chamber during
group 2 and 3 studies.
Acid-base metabolism. Several significant metabolic
and respiratory changes occurred in the patients in
groups I and 2 hemodialyzed with acetate-containing
dialysate (Table 4). The arterial carbon dioxide pres-
sure (P02) dropped during dialysis in group I and 2
patients; this was associated with low blood P02mea-
surements (10 mm Hg or less) in the venous dialyzer
line. Upon completion of dialysis, the arterial P02
rose rapidly. Group 3 patients had no depression of
arterial P02 and significantly (P > 0.005) higher
dialyzer venous blood values (38.2 0.7 mm Hg). In
groups I and 2, arterial P02 decreased by 10% early in
dialysis and then returned to baseline values; P02
changes for group 3 patients were not significant.
There was a small decrease in the minute ventilation
volume at one hour, but the values during or after
dialysis were not significantly different from the pre-
dialysis values of 7.5 liters/mm 2.1 (± I SD) (group
1), 9.5 3.0 liters/mm (group 2), and 7.4 3.0
liters/mm (group 3).
In groups 1 and 2, serum bicarbonate decreased
during dialysis (Table 4). The mean rate of bicarbo-
nate removal (NHCO3) was 47.5 tmo1es/min/kg of
body wt 7.1 (± 1 SD) in group 1 and 44.9 13.4
tmoles/min/kg in group 2. The calculated intra-
dialytic rate of bicarbonate generation ('HCO3)
was 42.9 ll.0tmoles/min/kg in group 1 and 41.9
13.0 pmoles/min/kg in group 2. Hence, the rate of
bicarbonate removal appeared to exceed that of gen-
eration in both groups, and no intradialytic progress
was made in correcting the predialysis total body
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bicarbonate deficit. In group 3 patients, the net influx
of bicarbonate across the dialyzer into blood resulted
in a prompt increase of serum bicarbonate.
In group 2, the bicarbonate concentration of the
recirculating chamber dialysate equilibrated at 4.2 +
1.3 mmoles/liter by mid-dialysis. This is in contrast
to the predictable absence of bicarbonate in the inlet
dialysate of the single pass system used in the group 1
patients. As a result of the lower concentration
gradient, less total bicarbonate was removed from
group 2 patients (676.0 154.0 mmoles) than from
group I patients (848.0 100 mmoles) (Table 5).
After cessation of dialysis, bicarbonate continued
to be generated from the remaining total body acetate
pool. Serum bicarbonate concentrations increased
until maximum levels were attained at four hours
after dialysis in groups I and 2 (Table 4). This rise
was significantly greater (P < 0.01) for group 1 than
for group 2 patients. At six hours after dialysis (two
patients from each group) no further bicarbonate
increase from four hour postdialysis levels had oc-
curred. There followed a steady decline to predialysis
values. As would be expected, there was no post-
dialysis rise in the arterial bicarbonate concentration
in group 3 patients.
The initial acid-base status of the patients studied
was consistent. Twenty-three of twenty-eight pre-
dialysis blood gas values indicated complete respi-
ratory compensation for the underlying metabolic
acidosis (pH > 7.35). In the remaining five individ-
uals, the mean predialysis pH was 7.33 + 0.01. Four
of the five were "new" patients to the program, but
none had an excessive preceeding interdialytic inter-
val (46.0 + 2.8 hr). Acid-base metabolism was other-
wise similar in both "new" and "established"
patients.
Hemodialysis resulted in higher blood pH values
for all groups (Table 4). In group I, the rise, com-
pared to predialysis values, does not attain statistical
significance until four hours after dialysis (P < 0.05);
the increase in group 2 was never statistically signifi-
cant. At the conclusion of dialysis, none of the
patients in group 1 and 2 had corrected their dimin-
ished total body bicarbonate.
The anion gap increased in group 1 and 2 patients
in association with increased plasma acetate levels
(Table 6). No significant changes in lactate or pyru-
vate occurred. The anion gap narrowed significantly
immediately after dialysis, concomitant with the de-
crease in circulating acetate.
Acetate metabolism. The mean acetate infusion rate
(TAC) for group 1 (59.8 moles/min/kg of body wt
10.0 [± 1 SD]) was significantly greater than for group
2 patients (49,7 + 8.0 tmoles/min/kg) (P < 0.01).
With the onset of dialysis, there was a prompt in-
crease in true arterial plasma acetate values (Fig. 1).
In group 2, these tended to plateau by mid-dialysis.
The values in group I were significantly greater than
in group 2 at all times and rose continuously through-
out dialysis (P < 0.01). The apparent maximum rate
of utilization of exogenous acetate was calculated to
be 48.0 9.0 imoles/min/kg (+ 1 SD).
Circulating acetate disappeared at a constant rate
for the first ten minutes after the cessation of dialysis
(Fig. 2); the kA was 200 50 tmoles/liter/min (± I
SD) in group I and 184 50 moles/liter/min in
group 2 (P > 0.1). In group 2, small (<1 mmole)
amounts of acetate were found at one hour after
dialysis in only two patients. In contrast, four group 1
patients had circulating levels of 1.0 to 5.1
mmoles/liter at the same time. Three of these four
patients were "new" patients. No circulating acetate
was found four hours after dialysis in any patient. No
other differences in acetate metabolism were noted
between "new" and "established" patients.
Estimation of entry of acetate into tricarboxylic acid
cycle. The amount of acetate infused during dialysis
was a direct function of the dialysate acetate concen-
tration (Table 5). The mean total amount of acetate
infused was 1048.3 tmoles 100.5 mmoles (±1 SD) in
Table 6. Anion gap, lactate and pyruvate changes during and after hemodialysis
Hr Anion gap, mEq/liter SD Lactate, mow/es/liter Pyruvate. minoles/liter
Group I Group 2 Group 3 Group I Group 2 Group 3 Group I Group 2 Group 3
0
I
2
3
4
8
24
48
22.4 + 3.8
28.1 + 2.5
28.2 2.4
29.3 2.8a
28.9 + 3.0
18.6 + 3.1
21.7 + 3.!
22.5 + 2.1
20.2 + 3.6
23.1 + 4.3"
24.7 5.2"
23.7 45"
24.6 + 6.0"
20.1 + 5.1
21.4 3.0
21.9 + 3.3
21.4 + 3.1
18.8 3.0
18.7 + 2.6
7.2 + 2.0'
17.9 2.2'
20.4 2.3
20.5 + 3.3
22.6 + 3.1
0.98 0.3
1.10 + 0.2
0.86 0.3
0.95 + 0.4
1.13 + 0.4
1.00 0.4
0.93 0.4
0.86 0.4
0.94 0.3
0.94 + 0.4
1.10 0.5
0.91 0.4
0.04 0.!
0.86 + 0.1
0.80 0.3
0.76 0.3
0.94 + 0.4
0.84 + 0.2
0.08 + 0.01
0.08 0.01
0.04 0.02
0.04 + 0.02
0.07 0.04
0.04 0.02
0.08 + 0.05
0.08 0.04
0.09 + 0.03
0.11 0.03
0.12 0.04
0.09 0.05
0.05 + 0.02
0.05 0.02
0.06 0.02
0.06 0.03
0.04 + 0.02
0.04 + 0.02
a Significance, group I vs. 2 (P < 0.05).
"Significance, group 2 vs. 3 (P < 0.0!).
Signilicance, group I vs. 3 (P K 0.01).
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group 1; this was significantly greater than that in-
fusion into group 2 (780.4 + 145.6) (P < 0.01). The
greater acetate infusion for group I ultimately re-
sulted in a larger amount of bicarbonate generated
over the eight-hour period comprising dialysis and
the first four hours after dialysis (group 1, 980.6 +
214.0 mmoles; group 2, 723.9 + 190.0 mmoles, P <
0.01). No bicarbonate or acetate loss in urine was
found during dialysis or the four-hour post-dialysis
period.
Our estimates of the percent of acetate metabolized
to bicarbonate (MAC) for each patient in group 1 were
66%, 83%, 91%, 94%, 100%, 102%, 106%, and 106%.
For group 2 patients, the estimates were 77%, 78%,
87%, 88%, 88%, 91%, 91%, 101%, 104% and 106%.
For all patients the estimated mean percent of acetate
converted to bicarbonate in the eight-hour period
was 93.5 4.8 (± 1 SEM) for group 1 and 91.1 + 3.5
for group 2. Thus, our estimates could account for
equimolar metabolic conversion of acetate in 50% of
group I patients and 30% of group 2.
Plasma lipids during hemodialysis. Forty-five per-
cent of the patients studied had fasting hypertrigly-
ceridemia, defined as a plasma triglyceride concentra-
tion greater than 140 mg/100 ml. Mean triglyceride
values were lower in "new" patients but this differ-
ence was not significant ("new": 116.3 + 58.4, I
SD; "established": 127.3 + 53.6, P > 0.1). No signif-
icant sexual bias in triglyceride levels was noted.
Plasma triglycerides fell significantly within 30 mm
of hemodialysis, reaching the lowest values by mid-
dialysis (Fig. 3). The mean decrease for all groups
was 52.5 3.0% (± I SCM) of the initial triglyceride
values with a range of 46 to 60%. There was no
significant difference in this decrease among the
groups (P > 0.1), and the triglyceride decrement
varied directly with the administered dose of heparin
in all groups (r = 0.82). Associated with the decrease
in triglycerides was a rise in the plasma total non-
esterified free fatty acids (Fig. 3). In group 1 and group
3, mean free fatty acid values were similar (P> 0.1).
The rise in plasma triglycerides after dialysis was
similar in all groups (P> 0.1). No significant change
in total plasma cholesterol occurred.
Predialysis lipoprotein electrophoretic patterns
uniformly revealed beta and pre-beta staining. Chylo-
microns were not noted in any patients. Pre-beta
stains disappeared early in dialysis and then reap-
peared during the immediate postdialysis period.
Serum acetoacetate concentration increased during
dialysis in all groups (Fig. 4). Peak values were 2.2
mmoles/liter 0.4 (± I SEM) in group 1, 0.60 + 0.2
mmoles/liter in group 2, and 0.50 0.2 mmoles/liter
in group 3. Group 1 acetoacetate concentrations were
significantly greater than groups 2 or 3 concentra-
tions by mid-dialysis (P < 0.005). Plasma acetone
concentration became detectable at four hours after
dialysis in six of eight patients in group 1 and seven of
ten in group 2. No significant amounts of acetalde-
hyde or ethanol were detected.
Discussion
The correction of metabolic acidosis by hem o-
dialysis requires an acetate concentration in the dialy-
sate which is sufficient to increase serum bicarbonate
levels, despite significant bicarbonate removal. Mion
and his co-workers determined that an acetate con-
centration of 35 to 40 mmoles/liter fulfilled this re-
quirement for standard surface area dialyzers [1].
However, large surface area hemodialyzers have en-
tered current clinical use in order to provide shorter
hours of hemodialysis [21]. These dialyzers transfer
acetate very efficiently and, when used with standard
commercial concentrates, deliver a large acetate load
to the patient. Our purpose was to investigate the
acute metabolic effects of this large acetate infusion.
The results of the study indicate that the metabolic
consequences of high mass-transfer hemodialysis
cause significant and complex changes in the acid-
base status of the chronic renal failure patient.
Solute mass-transfer. These data demonstrate the
efficient nature of solute transfer by the 2.5 m2 hollow
fiber dialyzer. In this study, in vivo dialysance data
for frequently measured solutes (creatinine, urea, and
uric acid) are similar to existing in Vitro determina-
tions at comparable blood flow rates [22].
Comparison data for glucose transfer for this
dialyzer was previously unavailable. Though the use
of glucose-free dialysate led to a measurable glucose
loss in these patients, it did not introduce a significant
energy deficit in patients of groups 1 and 2. The 200
Kcal derived from the metabolism of one mole of
infused acetate compensated for the potential caloric
loss of 129.6 + 21.6 Kcal from dialyzed glucose [23].
In fact, the patients of groups I and 2 were in positive
caloric balance during dialysis.
Acid-base metabolism. The impact of the high
mass-transfer dialysis on the acid-base status of
hemodialysis patients is depicted schematically in
Figure 5. The primary determinants involved are the
removal of carbon dioxide and bicarbonate from the
patient's blood and the infusion of acetate into the
patient.
The magnitude of the carbon dioxide mass-transfer
can be appreciated by noting: 1) the remarkable drop
in arterial Pc02 during dialysis (Table 4), 2) the ex-
tremely low Pc0. in the dialyzer venous blood lines,
and 3) that at a QB of 300 mI/mm, approximately 5%
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of the cardiac output each minute has almost its
entire content of carbon dioxide extracted [24]. Dur-
ing dialysis the arterial Pc02 would reflect the effects
of both alveolar ventilation and dialyzer diffusion.
The depressed arterial values observed in our
patients during dialysis are adequately explained by
carbon dioxide mass-transfer. Pulmonary hyperventi-
lation could theoretically explain the decreased arte-
rial P0 [5]; however, no increase in minute ventila-
tion occurred, and a trend toward alveolar
hypoventilation was observed in early dialysis. There-
fore, alveolar hyperventilation as the explanation of
respiratory alkalosis during dialysis is inconsistent
with our observations. Others have observed similar
venous dialyzer line P02 values [4] and minute venti-
lation volumes during dialysis [251. It is apparent that
carbon dioxide dialysance accounts for the early rise
in arterial pH which occurred in these patients.
In both groups I and 2, the mean rate of bicarbo-
nate removal exceeded the estimated mean intra-
dialytic rate of bicarbonate generation. As a result,
the serum levels of bicarbonate decreased during
dialysis, despite ongoing bicarbonate generation.
These results contrast to previous observations of
steadily rising intradialytic bicarbonate concentra-
tion [25, 261. These latter studies were done using
standard surface area dialyzers and lower blood flow
rates. We emphasize that in our patients the de-
pressed serum bicarbonate levels do not reflect a di-
minished ability to convert acetate, but merely in-
dicate a rapid bicarbonate removal which exceeds the
normal rate that one can expect bicarbonate to be
generated. These observations disagree with previous
studies interpreting similar results as "acetate intoler-
ance" in hemodialysis patients [5].
At the conclusion of hemodialysis, the preexisting
metabolic acidosis has been worsened (Fig. 5). In
clinically stable outpatients with chronic renal failure
and mild bicarbonate deficit, the acute bicarbonate
decrease is balanced by carbon dioxide removal by
the dialyzer, resulting in an actual increase in arterial
pH. However, in acutely ill patients with more severe
bicarbonate deficit and diminished buffer reserve, the
rapid bicarbonate removal could have serious con-
sequences. Therefore, the use of a large surface area
dialyzer and acetate-containing dialysate could lead
to deterioration of acid-base balance.
The dialysis delivery system utilized had a pro-
found effect upon bicarbonate removal by the hemo-
dialyzer. In the recirculating single pass system
(group 2), the equilibration of measurable amounts
of bicarbonate in the recirculating dialysate helped
attenuate bicarbonate removal and mitigated the
drop in arterial bicarbonate concentrations that was
observed with the single pass system. Since this effect
also applies to other solutes (urea, creatinine), the
clearance of these solutes was also diminished in the
recirculating pass system. While others have noted a
delivery system influence on dialyzer clearance [21],
the importance of this aspect to bicarbonate kinetics
has not been emphasized previously.
In contrast to previous reports of elevated lactate
and pyruvate levels [4, 26], we were unable to demon-
strate any significant change in these parameters. In
this study, the intradialytic increase in unmeasured
circulating anions could be accounted for by the in-
crease in the circulating acetate anion (Table 6).
As will be discussed, hemodialysis under our study
conditions appears to favor ketogenesis. During con-
ditions favoring ketogenesis, serum pyruvate levels
have been reported to decrease [7, 27] or remain
stable, which is consistent with our results.
Fig. 5. Acid-base kinetics during hetnodialysis with high mass-transfer hemodialyzers.
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When the alkalinizing salt is acetate, the interval
that follows dialysis is characterized by continued
bicarbonate generation and rapid increase in serum
bicarbonate concentrations. During this interval cir-
culating acetate disappears within two hours, but
maximum arterial bicarbonate levels are not reached
until four hours after dialysis. This delayed bicarbo-
nate rise probably represents transport and metabo-
lism of the remaining intracellular acetate. Others
have implied delayed acetate metabolism in patients
who continue to elevate their serum bicarbonate up
to 12 hr after dialysis [26]. We could not confirm the
latter observation. Postdialysis metabolic alkalosis
[3, 25, 26, 28] and its attendant complications to the
hemodialysis patient [29, 30, 31] have been described
earlier. It is apparent that bicarbonate buffered dialy-
sate produces a more physiologic correction of meta-
bolic acidosis [32, 33].
A cetale metabolism. The use of large surface area
dialyzers and high dialysate acetate concentrations
(40 mmoles/liter) results in acetate infusion of a mag-
nitude which exceeds the metabolic capacities of
dialysis patients. This leads to a progressive increase
in plasma acetate concentrations during dialysis (Fig.
I ).
When acetate was infused at the apparent max-
imum rate of utilization of exogenous acetate (group
2), a steady state was reached and serum concentra-
tions did not vary. Kveim and Nesbakken used an
analogous approach to obtain comparable data [3].
Group I studies indicate that increasing the rate of
acetate infusion does not further increase the intra-
dialytic rate of bicarbonate generation. At the con-
clusion of dialysis, the percent decrement in acetate is
constant until the acetate concentration no longer
saturates the metabolic systems (Fig. 2). In group
2, the disappearance curve splays below 3.0
mmoles/liter. This may represent the concentration
at which the metabolic rate of acetate varies with its
concentration. It would be expected, then, that after
initiation of dialysis, when the serum concentration
exceeds 3.0 mmoles/liter, a constant rate of acetate
utilization may occur. This can be seen in Figure 1.
While availability of coenzyme A may be important,
the rate-limiting factor in acetate metabolism is un-
known at present.
Acetate entry into the tricarboxylic acid cycle. Ear-
lier data had indicated that equimolar generation of
bicarbonate from acetate uniformly occurs during
dialysis [I]. The latter investigation was performed
on a few patients with smaller surface area hemo-
dialyzers operating at lower blood flow rates. Our
results suggest that estimated acetate entry into the
tricarboxylic acid cycle may be more variable. We
found that equimolar oxidative generation of sodium
bicarbonate from sodium acetate does not occur in
the majority of patients. This disparity could result
from the experimental conditions of our in-
vestigations.
Our estimation of acetate entry into the tricarboxy-
lic acid cycle is an indirect method which is based
upon assumed alterations in total body bicarbonate
attendant to hemodialysis (Appendix, equations 7a to
f, 8). The basic assumption of our method depends
upon the total body water and the bicarbonate space
remaining constant. Water loss during hemodialysis
in our patients resulted in a contraction of the total
body water compartment of less than 1.5% during
these studies. Based upon changes in the estimated
total body bicarbonate, four out of eight patients in
group I and seven out of ten patients in group 2 did
not appear to have equimolar conversion of acetate
to bicarbonate. If these estimates are correct, this
would provide a significant amount of acetate that
would theoretically be available to enter alternate
metabolic pathways.
Lipsky et al have reviewed the subject of ketone
production in man [7]. They have noted that sodium
acetate infusion into individuals leads to a rise in
serum ketones. This rise was attributed either to alka-
losis or acetate condensation. Additional ex-
planations are possible in our patients. Fasting, as
well as heparin-induced lipolysis can lead to elevated
plasma free fatty acid concentrations and subsequent
ketone production. However, the latter factors were
operative in groups 3 patients, and although they
were the only group in negative caloric balance, they
had the least amount of ketone formation. Patients in
group I received the largest acetate infusions, and
they raised their plasma acetoacetate levels signifi-
cantly higher than did patients in group 2. The blood
pH change for both groups was similar and did not
rise during the intradialytic period. Acetate con-
densation, therefore, would appear to be the primary
ketogenic mechanism in these subjects.
Plasma lipids during hemodialysis. Fasting hyper-
triglyceridemia has been widely observed in uremic
patients [34, 35]. Our data are consistent with these
observations. We attribute the decrease of triglyc-
erides during hemodialysis to the effect of heparin on
lipoprotein lipase activity for the following reasons:
1) there was a direct statistical correlation of the
triglyceride decrease and the amount of heparin in-
fused, 2) the disappearance of pre-beta staining from
the lipoprotein electrophoresis occurred at the same
time, and 3) the simultaneous reappearance of pre-
beta staining with rising triglyceride levels after
dialysis. The rise in plasma free fatty acids during
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dialysis further documents the triglyceride lipolysis.
A similar rise has been reported by others [36].
Triglyceride resynthesis proceeds in the active meta-
bolic interval immediately after dialysis.
In this study, the effect of a solitary dialysis and its
related acetate infusion does not appear to be differ-
ent from bicarbonate buffered dialysis in its effects on
the level of plasma triglycerides. However, we recog-
nize that this does not clarify whether recurrent in-
fusion of large amounts of acetate would ultimately
influence triglyceride values.
We conclude that solute transfer during hemo-
dialysis with large surface area dialyzers has signifi-
cant impact on the acid-base and metabolic status of
the patient as follows: I) carbon dioxide dialysance
results in an early pH increase during dialysis, 2)
bicarbonate removal appears to exceed bicarbonate
generation as evidenced by the fall in serum bicarbo-
nate during dialysis, 3) under conditions of the
study, the infusion of acetate exceeds the maximum
utilization rate of exogenous acetate and results in
increased plasma acetate levels during dialysis, 4)
with massive acetate infusion, bicarbonate generation
after dialysis results in the development of significant
alkalosis, 5) under these experimental conditions ace-
tate may enter alternate pathways of metabolism and
may not entirely be accounted for by bicarbonate
generation, 6) it appears that an acetate concentra-
tion of 40 mmoles/liter in the dialysate may have
significant adverse metabolic effects when used with a
2.5 m2 hollow fiber dialyzer and single pass delivery
system, and 7) the rise in non-esterified free fatty
acids and decrease in plasma triglycerides can be
directly attributed to the heparin administered during
dialysis.
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Clearance (C):
C(liters/min) = QBICBI — (Q QF)CBO Ia
where C is the solute concentration at the dialyzer
blood inlet (mmoles/liter), CB0 is the solute concen-
tration at the dialyzer blood outlet, Q'. is the blood
flow rate into the dialyzer (liters/mm), and QF is the
ultrafiltration rate (liters/mm).
Dialysance (D):
D(liters/min) = Q1C,
CB—CD,
lb
where CD is the solute concentration at the dialysate
inlet (mmoles/liter).
Mass transfer rate (N)for acetate (Ac) (acetate in-
fusion rate):
NAC (mmoles/min) = (QB, — QF)CBOA Q11C 2a
Blood concentration of acetate at dialyzer inlet
(ColA):
C05 (mmoles/liter) = CpIAC [(1 — fRBc) +
0.59(fRBc)]
2b
where CPjAC is the plasma concentration of acetate at
the dialyzer blood inlet (mmciles/liter), fRBC is the
fraction of blood volume occupied by the red blood
cells (hematocrit), and 0.59 is the fractional amount
of acetate in RBC's relative to plasma in the blood
entering the dialyzer.
Blood concentration of acetate at the dialyzer outlet
(CBOA).'
CubA (mmoles/liter)
= CPOA[(1 — fRuc) + 0.49 (fRBc)1l 2c
where CpQAC is the plasma acetate concentration at the
diayzer blood outlet.
A cetate kinetics calculated from NAC:
Acetate infused (Inf. Ac) each hour(12,3.4) (mmoles):
Inf. Acl,2,S4 NAC•6O , 3a
where NAC is calculated from the mean concentra-
tions of acetate for each hourly period of dialysis.
Total acetate infused (T. Inf. Ac):
T. Inf. Ac (mmoles) = Inf. Ac1 + lnf. Ac2
+ lnf. Ac3 + lnf. Ac4 3b
To/chin et a!
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Appendix
Calculations Jr acetate and bicarbonate kinetics of
hemodialysis
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Mean acetate infusion rate (IAC): Amouni of bicarbonate generation (T.HCO3G):
NA (tmoles/min/kg) T. HCO (mmoles) = TBHCO — HCO 7f
Estimated percent of infused acetate metabolized to
—
1. inf. Ac X 1000 bicarbonate (MAC).- w
T.HCO3where W is the body wt in kg. MAC = T.lnf. Ac >< 100 8
Maximum rate of utilization of exogenous acetate
(RAC): Mean intradialytic bicarbonate generation rate
(r(HCO,):
RAC (imoles/min/kg) Total body bicarbonate at 4th hr of dialysis
(T B H CO34 ):Inf Ac(1234)
w''' X X 1000 TBHCO34 (mmoles) = 0.6 X W X HCO; 9a
where HCO3 is the serum bicarbonate concentrationAcetate disappearance rate (kAC):
at the 4th hour of dialysis. The following equation
Ac0 — Ac mm applies for TBHCO;:kAC (pmoles/liter/min) = 6X mm TBHCO34 (mmoles) = TBHCO3pr4 + HC030 —
where Ac0 is the plasma arterial concentration at four T.HCO
hours (completion) of dialysis (.smoles/liter), Acxmmn where HCO3 is the amount of bicarbonate generated
is the arterial concentration x minutes after the termi- during the dialysis. The above equation can be rewrit-
nation of dialysis. ten to solve for HCO3:
Amount of bicarbonate (HCO3) generation: HCO3 (mmoles) = TBHCO34 + THCOr —
Total body HCO3 predialysis (TBHCO3pre): TBHCO3p,e 9b
TBHCO3pre (mmoles) = 0.6 >< W >< HCOre 7a Mean rate of bicarbonate generation during dialysis
where 0.6 is the estimated space of bicarbonate distri-
bution as 60% of total body wt, and HCO3pre j5 the
predialysis serum bicarbonate concentration in RHCO3 (tm oles/min/kg)
mmoles/liter.
HCO3g I x 1000 9cAmount of bicarbonate removed (HCO3r) hourly = w
(mmoles):
Mean rate of bicarbonate removal during dialysis
HCOS,(l,2,...X) = 60 [QnmCumn — (QB1 — QF)CB017b (1HcO3):
where CB— is the mean bicarbonate concentration NHCO, (imoles/min/kg)H COain the arterial dialyzer line for any given hour, and
C3 is the mean bicarbonate concentration in the T.HCO3r
venous dialyzer line for the same period. = w X X 1000 10
Total bicarbonate removed (T. HCO):
T. HCO;(mmoles) = HCO3r1 + HCO3r2 + HCO3r3 References
+ HCO3r4 7c I. Mio C, HEGSTROM R, BOEN S, SCRIBNER B: Substitution of
Nonextracted body bicarbonate (HCO3): sodium acetate for sodium bicarbonate in the bath fluid for
hemodialysis. Trans Am Soc Art/f intern Organs 10:110—113,
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Total body bicarbonate at 4 hr after dialysis man. Nature 193:579—580, 1962
(TBHCO3): 3. KvEmM M, NESBAKKEN R: Utilization of exogenous acetate
during hemodialysis. Trans Am Soc Arlif intern Organs
TBHCO3 mmoles) = 0.6 X W X HCO, 7e 21:138—143, 1975
4. GONZALEZ F, PEARSON J, GARBUS 5, HOLBERT R: On the
where HCO, is the highest serum bicarbonate con- effects of acetate during hemodialysis. Trans Am Soc Artif
centration (4 hr) after dialysis. intern Organs 20:169—174, 1974
378 To/chin et a!
5. NOVELLO A, KELSCEI R, EASTERLING R: Acetate intolerance
during hemodialysis. Clin Nephro/ 5:29—32, 1976
6. ALTMAN P, DITTMER D (eds.): Metabolism. Bethesda, Feder-
ation of American Societies for Experimental Biology, 1971, p.
423
7. LIPSKY S. ALPER B, RuEINI M, VAN EcK W, GORDON M: The
effects of alkalosis upon ketone body production and carbohy-
drate metabolism in man. J Clin Invest 33:1269—1276, 1954
8. WOLF A, KEMP D, KILEY J, CURRIE G: Artificial kidney func-
tion: Kinetics of hemodialysis. J Clin Invest 30:1062—1070,
1951
9. SIGAARD-ANDERSON 0: Titratable acid or base of body fluids.
AnnNYAcadSci 133:41—58, 1966
10. THOMAS Li: Algorithms for selected blood acid-base and
blood gas calculations. J AppI Physiol 33:154—158, 1972
II. LANDON J, FAWCETT J, WYNN V: Blood pyruvate concentra-
tion measured by a specific method in control subjects. J Clin
Pathol 15:579—584, 1962
12. SINGER R, CLARK J, BARKER E, CROSLEY A, ELKINTON J: The
acute effects in man of rapid intravenous infusion of hyper-
tonic sodium bicarbonate solution. Medicine 34:51—95, 1955
13. EDELMAN I, LEIBMAN J: Anatomy of body water and elec-
trolytes. Am J Med 27:256—277, 1959
14. HAMWI G, URBACH S: Body compartments. Metabolism
2:391—403, 1953
IS. KESSLER R, LEDERER D: Automation in Analytical Chemistry.
New York, L. T. Skeggs Co., 1965, pp. 341—344
16. TROTTER M, SULWAY M, TROTTER E: The rapid determination
of acetone in breath and plasma. C/in Chim Ac/a 35:137—143,
1971
17. FREE I-I, SEIEBY R, COOK M, FREE A: A comparative study of
qualitative tests for ketones in urine and serum. C/in Chem
4:323—330, 1958
18. FALHOI.T K, LUND B, FALHOLT W: An easy calorimetric micro
method for routine determination of free fatty acids in plasma.
C/in Chi,n Ac/a 46:105—Ill, 1973
19. MIKAC-DEVIC C, STANKOVIC I-I, Boscovic K: A method for
determination of free fatty acids in serum. Clin Chim Acta
45:55—59, 1973
20. ARMITAGE P: Statistical Methods in Medical Research. New
York, J. Wiley and Sons, 1971, pp. 104, 150
21. KURvII.A M, CADNAPAPHORNCHAI F, LEASOR G, POPOVTZER
M, ALFREY A, SCURIER R: A model for evening home hemo-
dialysis. Am J Med 57:706—713, 1974
22. WHITIER F, COHLMIA J, GRANTHAM J: Evaluation of henio-
dialyzers with an endogenous marker of "middle molecules."
Ahstr Am Soc Artif Intern Organs 4:45, 1975
23. ORTEN J, NEUHAUS 0: Human Biochemistry (9th ed). St.
Louis, C. V. Mosby Co., 1957, p. 173
24. Goss J, ALFREY A, VOGEL J, HOLMES J: Hemodynamic changes
during hemodialysis. Trans Am Soc Art if Intern Organs 13:68—
74, 1967
25. EARNEST D, SADLER J, INGRAM R, MACON E: Acid-base bal-
ance in chronic hemodialysis. Trans Am Soc Ar/if Intern Or-
gans 14:434—437, 1968
26. ROSENBAUM B, COBURN I, SFIINABERGER J, MASSRY S: Acid-
base status during the interdialytic period in patients main-
tained with chronic hemodialysis. Ann Intern Med
71:1105—1111, 1968
27. KREBS H: The biochemical lesion in ketosis. Arch Intern Med
107:119—130, 1961
28. BLUMENTHALS A, EICHENHOI.Z A, MULHAUSEN R: Acid-base
changes during hemodialysis. Metabolism 14:667—673, 1965
29. EGGER Ii, BLUMBERG A, MARTI H: Acid-base balance and
oxygen affinity of hemoglobin in patients on maintenance
dialysis. C/in Nephrol 1:70—75, 1973
30. TORRANCE J, MILNE F, 1-IuRowiTz S, Zwi S, RABKIN R:
Changes in oxygen delivery during hemodialysis. C/in Nephrol
3:54—59, 1975
31. PARFITT A: Soft tissue calcification in uremia. Arch Intern Med
124:544—556, 1969
32. WELLER I, SWAN R, MERRILL I: Changes in acid-base balance
of uremic patients during hemodialysis. J C/in Invest
32:729—735, 1953
33. HENDERSON L, RODRIGUEZ B, BLUEMLE L: Factors in-
fluencing blood pH changes during extracorporeal dialysis in
patients with chronic renal failure. Trans Am Soc Ar/if Intern
Organs 12:193—199, 1966
34. BAGDADE I, PORTE D, BIERMAN E: Hypertriglyceridemia: A
metabolic consequence of chronic renal failure. N EngI J Med
279:181—185, 1968
35. BAGDADE J: Uremic lipemia: An unrecognized abnormality in
triglyceride production and removal. Arch Intern Med
126:875—881, 1970
36. TSAI.TAS T, FRIEDMAN E: Plasma lipid studies of uremic
patients during hemodialysis. A,n J C/in Nutr 21:430—435,
1968
